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Abstract
Background: Comorbidity between Attention Deficit Hyperactivity Disorder (ADHD) and mood disorders is common.
Alterations of the cerebellum and frontal regions have been reported in neuro-imaging studies of ADHD and major depression.
Methods: Thirty chronically depressed adult females of whom 16 had scores below, and 14 scores above, cut-offs on the 25-
items Wender Utah Retrospective Scale (WURS-25) and the Wender-Reimherr Adult Attention Deficit Disorder Scale
(WRAADDS) were divided into subgroups designated "Depression" and "Depression + ADHD", respectively. Twenty-one of
the patients had some audiological symptom, tinnitus and/or hearing impairment. The patients were investigated with other
rating scales and 99mTc-HMPAO SPECT. Controls for 99mTc-HMPAO SPECT were 16 healthy females. SPECT was analyzed by
both statistical parametric mapping (SPM2) and the computerized brain atlas (CBA). Discriminant analysis was performed on the
volumes of interest generated by the CBA, and on the scores from rating scales with the highest group differences.
Results: The mean score of a depression rating scale (MADRS-S) was significantly lower in the "Depression" subgroup
compared to in the "Depression + ADHD" subgroup. There was significantly decreased tracer uptake within the bilateral
cerebellum at both SPM and CBA in the "Depression + ADHD" subgroup compared to in the controls. No decrease of
cerebellar tracer uptake was observed in "Depression". Significantly increased tracer uptake was found at SPM within some
bilateral frontal regions (Brodmann areas 8, 9, 10, 32) in the "Depression + ADHD" subgroup compared to in "Depression". An
accuracy of 100% was obtained for the discrimination between the patient groups when thalamic uptake was used in the analysis
along with scores from Socialization and Impulsivity scales.
Conclusion: The findings confirm the previous observation of a cerebellar involvement in ADHD. Higher bilateral frontal
99mTc-HMPAO uptake in "Depression + ADHD" compared to in "Depression" indicate a difference between these subgroups.
99mTc-HMPAO uptake mechanisms are discussed.
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Background
The persistence of Attention Deficit Hyperactivity Disor-
der (ADHD), previously thought of as a self-limiting con-
dition that rarely requires treatment in adult life, has only
come into focus of widespread clinical attention and
research in the last decade. In 1998, it was suggested that
ADHD may be "the most common chronic undiagnosed
psychiatric disorder in adults" [1]. According to a U.S. sur-
vey estimation, the prevalence of adult-ADHD may be as
high as 4.4% [2]. Higher medical costs and more absences
from work are associated with ADHD in adults [3]. Life-
time mood disorder was reported by 53% of the patients
with adult-ADHD, versus in 28% of the controls, in a
study [4]. It has been suggested that the complex emo-
tional symptoms in females with adult-ADHD may
obscure the diagnosis of ADHD [5]. An earlier age of onset
of major depression, and a comorbidity of 87% with at
least one other psychiatric disorder, was reported in a
study of adult-ADHD subjects compared with non-ADHD
subjects [6]. For the psychiatric and somatic comorbidity
with adult-ADHD, see [Additional file 1].
High heritability of ADHD irrespective of whether contin-
uum or categorical approaches were used, or if different
cut-off criteria were applied, was reported in a large twin
study [7]. The requirement of specific numbers of symp-
toms to be present may impose an artificial categorical
construct. Sachdev has suggested that adult-ADHD should
be studied without restricting the examination to those
meeting some arbitrary diagnostic criteria [8].
Similarities between adult and childhood ADHD such as
impaired cerebello-(thalamo)-striato-frontal networks
have been suggested [9]. In a study of magnetic resonance
imaging (MRI) in adult-ADHD, there was significantly
smaller volumes of the overall cortical grey matter, and
prefrontal and anterior cingulate cortex, while total cere-
bral volume was normal, compared to healthy controls
[10]. Decreased global cerebral glucose metabolism in
adult-ADHD at Positron Emission Tomography (PET),
with regional reductions in several regions including the
premotor and the superior prefrontal cortex, has been
reported [11]. Less activation at decision making in adult-
ADHD at PET using O-15 labeled water was observed in
brain regions including Brodmann area (BA) 32 in the
anterior cingulate cortex [12].
Single Photon Emission Computed Tomography (SPECT)
is the mostly available functional neuro-imaging method.
SPECT systems detect γ-rays emitted by injected radioac-
tive substances.
The uptake of the radiotracer 99mTc-d,l-hexamethylpropyl-
ene amine oxime (99mTc-HMPAO) used at SPECT is gen-
erally considered to reflect cerebral blood flow (CBF).
However, discrepancies in the same brains have been
reported between the uptake of 99mTc-HMPAO and other
SPECT perfusion tracers, and with PET results [13-15].
Such differences may be related to the specific retention
mechanism of 99mTc-HMPAO [13].
The aims of the present study
The main aim of the study was to identify any regional
CBF differences as reflected by the brain uptake of 99mTc-
HMPAO in chronically depressed females subdivided for
the absence or presence of adult-ADHD, and in healthy
controls. The second aim was to find etiological models
for any emerging differences. The third aim was to identify
factors accounting for most of the differences between the
patient groups.
Materials and methods
Subjects
Subjects were 30 adult females (ages 26-58 years, mean 43
± 10) attending a specialized tertiary psychiatric hospital-
affiliated out-patient unit for clients with any type of audi-
ological symptom and their relatives in need of psychiat-
ric care. All subjects had an ongoing chronic (at least two
years) depressive disorder fulfilling the DSM-IV criteria for
major depression [16] at least once. In 21 patients there
was tinnitus, hyperacusia, vertigo, and/or hearing impair-
ment. The hearing impairment was severe with childhood
onset in five patients. Nine patients without any audiolog-
ical symptoms had first-degree relatives with audiological
and psychiatric symptoms. Exclusion criteria were austis-
tic disorders, bipolar disorder, psychosis, antisocial per-
sonality disorder, alcohol or other substance abuse/
dependence, or serious medical illness. Eighteen patients
(60%) were free of any psychiatric medication at the time
of the SPECT scan apart from sleeping agents in some
patients. Nine patients (30%) were medicating with anti-
depressant agents, and three patients with anxiolytic
agents (10%). Two of the antidepressant-medicated
patients had other ongoing medication, in one case
quetiapin, in the other modafinil. The SPECT scans were
obtained at an out-patient basis in all patients when they
were in their habitual state and not during episodes of
increased mood symptomatology.
ADHD-questionnaires
The patients were subgrouped according to their self-rated
scores on the 25-items version of the Wender Utah Retro-
spective Scale (WURS-25), and the Wender-Reimherr
Adult Attention Deficit Disorder Scale (WRAADDS). A
cut-off score of 36 for WURS-25, which has a 5-point
response format, was applied since it had been shown to
correctly identify 96% of an ADHD group, and 96% of the
non-patient comparison group in a study [17]. CurrentBehavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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adult-ADHD-like symptoms were assessed with the 35-
items 5-point response format WRAADDS [5]. The
WRAADDS has seven subscales: Attentional Difficulties,
Hyperactivity/Restlessness, Temper, Affective Lability,
Disorganization, Stress Sensitivity, and Impulsivity. The
instruction for the WRAADDS questionnaire was changed
from "during all your adult life" into "during the past
years". A cut-off score of 50 was chosen since depressed
patients with lower scores usually deny any clinically sig-
nificant cognitive symptoms according to clinical experi-
ence. The results of the questionnaires were presented to
the patients who then were interviewed about past and
current ADHD symptomatology. Scores below cut-offs are
referred to as "low", and at/above cut-offs as "high" in the
following text.
Mood and personality questionnaires
The self-rated 9-items version of the Montgomery Aasberg
Depression Rating Scale with a 6-point response format
[MADRS-S; [18]], was used to assess current mood at
SPECT. The 20-items Socialization subscale from the self-
rated Karolinska Scales of Personality (KSP) with a 4-
point response format was used to assess the dimensions
of alienation, victimization, resentment and dysphoria.
The KSP Socialization scale has been adapted from the
Swedish translation and psychometric analysis of the Cal-
ifornia Psychological Inventory (CPI) Socialization scale
and contains items dealing with negative childhood expe-
riences [19]. The Socialization scale possesses remarkable
stability over time both in a population sample [20] and
in depressed patients [21]. The scores of the patients were
compared with normative data transformed to T-scores
(50 ± 10) obtained from 200 females randomly sampled
from the Stockholm population and standardized for gen-
der and age [19]. Low scores at Socialization indicate
pathology.
Neuropsychological investigation
Five patients with high WURS-25 and WRAADDS scores,
all adult daughters with normal hearing of hearing
impaired mothers, were thoroughly investigated with a
neuropsychological test battery at a specialized neuropsy-
chiatric unit. The investigation included clinical inter-
views (in four cases also with mother/parents),
questionnaires, rating scales, and neuropsychological
tests including the computerized visual Test of Variables
of Attention [T.O.V.A.; [22]].
Healthy controls for SPECT
Sixteen healthy adult females (ages 25-56 years, mean 40
± 13), all with normal MADRS scores, served as controls.
They were selected from a group of individuals who had
undergone SPECT with the intention that they would be
utilised as a normal control group for SPECT analyses
[23]. The study was approved by the local Ethics and Radi-
ation Safety Committees (Karolinska sjukhuset Nord 97-
141; KI(Syd)HS 423:00; Regionala etikprövningsnäm-
nden 04-1079/1; Strålskyddskommittén, Karolinska Uni-
versitetssjukhuset, Solna, Stockholm 03/05). All subjects
gave written informed consent.
SPECT
Brain imaging using SPECT was performed using a three-
headed Gamma Camera (TRIAD XLT 20, Trionix Research
Laboratory Inc., Twinsburg, OH, USA) equipped with
low-energy ultrahigh-resolution (LEUHR) collimators.
The intrinsic spatial resolution of the camera was 8 mm at
Full Width Half Maximum. 99mTc-HMPAO (Ceretec®,
Exametazine, Amersham International Plc, Little Chal-
font, UK) was injected after 30 minutes rest in a quiet dim
lighted room. Examinations started between 45 and 60
minutes after tracer injection. The projection data were
acquired for 30 seconds per projection at 90 equal angles
of a complete revolution. Between 8 and 10 million total
counts were acquired.
Before back-projection we pre-processed the one-dimen-
sional data with a Hamming smoothing filter with a cut-
off frequency of 2.25 cycles/cm. Then SPECT images were
reconstructed by filtered back projection algorithm using
a ramp filter with a cut-off frequency of 0.6 cycles/cm.
Attenuation correction was based on a four-point ellipse
[24]. No scatter correction was performed. Data were pro-
jected into a 128 × 128 pixel matrix resulting in an iso-
tropic voxel size of 2.2 mm3.
SPM2 analysis
SPECT raw images were transformed into the analyze for-
mat by XMedCon package. Data were analyzed with SPM2
(Wellcome Department of Cognitive Neurology, London,
UK) implemented in Matlab 6.5.1. Images of relative
tracer distribution were spatially normalized into the ster-
eotactic Montreal Neurological Institute (MNI) space, a
predefined SPECT template available in SPM2 (voxel size
2 × 2 × 2 mm), using a 16-parameter affine (non-linear)
transformation. Because this template doesn't completely
match the Talairach brain, it was necessary to correct the
SPM{t} coordinates. This was achieved using the subrou-
tine implemented by Matthew Brett [25]. BAs where then
identified within a range of 3 mm, after importing the cor-
rected coordinates, by the Talairach Daemon Database
[26].
After normalization, images were smoothed with a Gaus-
sian filter of 12 mm (FWHM) to account for individual
gyral differences and brain anatomy and to increase the
signal-to-noise ratio. Images were globally normalized for
signal intensity using proportional scaling to remove con-
founding effects due to global CBF changes, with a thresh-
old masking for grey matter of 0.8, allowing to includeBehavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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into the analysis only those voxels whose intensity
exceeded the 80% of the maximal one.
The voxel-based analyses were performed using SPM2
with a "one scan per subject, Ancova" design model, and
significances were sought for the contrasts between
healthy controls and the patient groups, and between the
patient groups.
CBA analysis
For non-voxel based evaluation and analysis, the SPECT
data were analyzed by a computerized brain atlas (CBA;
Applied Medical Imaging AB, Uppsala, Sweden) [27]
allowing for identification of various anatomical brain
structures. All image sets were spatially normalized into
the stereotactic space of the atlas by using the global pol-
ynomial transformation. It consists of translations, rota-
tions and linear scaling along and around each of the
three image axes. It also contains 18 nonlinear shape-
deforming parameters, which make it possible to individ-
ualize the brain shape. Then when needed, further man-
ual adjustments were performed to optimize the fitting of
the CBA contours to both external and internal (brain
ventricles) borders. In order to obtain a set of normalized
relative metabolic data, a scaling factor was computed
averaging all brain voxels data and setting the global brain
average to the conventional value of 50 'uptake units'. All
regional uptake values were then related to this value.
Normalized tracer uptake for 54 volumes of interest
(VOIs), 27 from each hemisphere, was automatically
assessed by the CBA. Each VOI was automatically built up
by summing the corresponding regions of interest in con-
secutive sections. The selected VOIs were thalamus,
nucleus caudatus, putamen, insular region, hippocampus,
cerebellum, and BAs from the frontal, temporal, parietal,
and occipital lobes, and the cingulate cortex.
Discriminant analysis
Stepwise discriminant analysis was performed to compare
clinical diagnosis as determined by the ADHD question-
naires and interview to the grouping according to some of
the variables under investigation. This exploratory analy-
sis was especially performed in order to identify the diag-
nostic factors accounting for the most of the group
differences. The outcome of discriminant analysis resulted
in discriminant functions (DF) that are the linear combi-
nations of variables included in the analysis. The rele-
vance of a DF is given by its canonical correlation (R), i.e.,
the total variance explained by each DF (R, 0-1). On the
basis of the scores computed for each subject, a classifica-
tion matrix was computed to evaluate the efficiency of the
analysis. Cases were classified as belonging to the group
where the highest classification score was reached. Signif-
icance of the discriminant analysis was tested with aprox-
F value.
Statistical analysis
A threshold of p < 0.01 was set for the group differences
on demographic data and rating scores. For group differ-
ences at SPM2, thresholds of p = 0.01 uncorrected for
multiple comparisons for voxel height, pcorrected < 0.05 at
cluster level and puncorrected < 0.001 at voxel level were cho-
sen. At voxel level, the false discovery rate (FDR) method
for multiple comparison correction was also explored. In
this latter case voxels were considered significant at a pcor-
rected < 0.05. Only those clusters containing more than 200
voxels were accepted as significant. This was based on the
calculation of the partial volume effect resulting from the
spatial resolution of the camera system. The significance
threshold for the CBA analyses was set at p < 0.05.
Results
Subgrouping of patients according to ADHD-
questionnaires and interview
The patients with low WURS-25 and WRAADDS scores
were designated as the "Depression" subgroup (N = 16),
and the patients with high WURS-25 and WRAADDS
scores as the "Depression + ADHD" subgroup (N = 14).
The patients endorsed the absence or presence of the
ADHD symptoms as assessed by the questionnaires at the
interview subsequent to filling in the ADHD-question-
naires. Two of the five patients with early hearing impair-
ment were included in the "Depression" subgroup, and
three in the "Depression + ADHD" subgroup. Three of the
nine patients without audiological symptoms were
included in "Depression", and six in "Depression +
ADHD".
Neuropsychological investigation
The results of the thorough investigation of five patients
included in the "Depression + ADHD" subgroup con-
firmed ADHD in three patients, and the predominantly
inattentive subtype, Attention Deficit Disorder (ADD), in
two patients.
Demographic and other data in the patient groups
Demographic and other data are presented in Tables 1 +
2. Since age differed between the patient subgroups, it was
considered as a nuisance variable in the comparisons
between "Depression + ADHD" and "Depression" at both
SPM2 and CBA. There were no proportional significant
differences for work capacity, co-habitation with a part-
ner, motherhood, or medication at SPECT. The "Depres-
sion + ADHD" patients were significantly younger at their
own estimation for first onset of mood symptoms. There
was no significant difference for years spent since onset of
mood symptoms ("Depression": 14 ± 12 years, "Depres-
sion + ADHD": 19 ± 12 years, p = 0.237). The scores at the
depression rating and Socialization were significantly
more abnormal in the "Depression + ADHD" subgroup.Behavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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Comparisons of the tracer uptake at SPECT between 
controls and patients
The SPM subtraction for the healthy controls minus
"Depression + ADHD" revealed significantly decreased
tracer uptake within the bilateral cerebellum in the patient
group (pcorrected = 0.024 at cluster-level and puncorrected <
0.001 at voxel-level), see Figure 1. No significant differ-
ences were found at the opposite comparison. When the
controls were compared to "Depression", no significant
changes were found at both subtractions.
At the CBA evaluation, an Hemisphere*VOIs*GROUP
interaction (F(26,728) = 1.749, p < 0.05) was found.
There was decreased tracer uptake in the "Depression +
ADHD" subgroup compared to controls in the bilateral
cerebellum (F(1,28) = 13.429, p < 0.001) and in the cau-
date nuclei (F(1,28) = 10.013, p < 0.01).
Comparisons of the tracer uptake at SPECT between the 
patient groups
The SPM subtraction for the "Depression + ADHD" minus
"Depression" revealed a large cluster of highly signifi-
cantly increased tracer uptake (pcorrected < 0.001 at cluster-
level; puncorrected < 0.001 and pFDR-corrected = 0.013 at voxel
level) in "Depression + ADHD" within the bilateral BA 32
in the anterior cingulate cortex, in BAs 8, 9 and 10 in the
prefrontal and middle frontal cortex, and in large portions
of the frontal lobe white matter, see Figure 2. No signifi-
cant differences were found at the opposite comparison.
The SPM findings are summarized in Figure 3.
When implementing the CBA in the "Depression +
ADHD" versus "Depression" comparison, there was a sig-
nificant VOIs*GROUP (F(26,728) = 1.605, p < 0.05)
interaction. Tracer uptake was significantly decreased in
"Depression + ADHD" as compared to "Depression" in
the putamen (F(1,28) = 6.525, p < 0.05) and in the thala-
mus (F(1,28) = 5.209, p < 0.05).
Discriminant analysis
In discriminating between "Depression" and "Depression
+ ADHD", the WRAADDS subscale Impulsivity, the KSP
subscale Socialization, and the thalamic tracer uptake
were found to be the most useful variables. The 6-items
Impulsivity subscale constitutes 17% of the WRAADDS
items (mean scores "Depression": 3 ± 2, "Depression +
ADHD": 15 ± 4, p < 0.0001). Results for Socialization are
presented in Table 1. Using these variables, the percentage
of correct classification as compared to clinical diagnosis
reached 100% in both sensitivity and specificity
(Aprox.F(3,25) = 49.42, p < 0.001). The canonical corre-
lation was 0.925 yielding a 85.6% of total variance
explained by our grouping.
Discussion
In this study we report decreased 99mTc-HMPAO uptake in
the cerebellum at SPECT in chronically depressed females
with adult-ADHD. No decrease of cerebellar 99mTc-
HMPAO uptake was observed in chronically depressed
females without ADHD. A relative increase of tracer
uptake mainly in the frontal and anterior limbic cortex
was found in the "Depression + ADHD" subgroup as com-
pared to in "Depression". Self-rated scores for ADHD
symptomatology followed by clinical interview were used
to divide all the patients into subgroups with likely
absence or presence of adult-ADHD. The DSM-IV-criteria
for ADHD [16] were not applied since they refer to ADHD
without concomitant mood disorder. The diagnosis of
adult-ADHD/ADD was supported in those patients in
whom neuropsychological evaluations were performed
by a specialized team.
Table 1: Demographic and other data
Subgroup/p-values No of cases Age WURS-25 WRAADDS
< 40 considered normal
≥ 70 indicates ADHD
Socialization
50 ± 10 normal
(low score abnormal)
Age at first onset of mood 
symptoms
(patients' own estimation)
"Depression" 16 47 ± 9 15 ± 8 37 ± 11 43 ± 10 33 ± 12
"Depression + ADHD" 14 39 ± 9 59 ± 18* 89 ± 16 22 ± 10** 18 ± 13
t-test p-value 0.029 0.0000 0.0000 0.0000 0.004
*The WURS-25 score in one patient and included here: 31 (as assessed by mother: 42). **13 patients.
Table 2: Demographic and other data
Subgroup/p-values No work capacity Not married or living 
with partner
No children MADRS-S Anti-depressant 
medication
Anxiolytic medication
"Depression" 12/16 7/16 3/16 16 ± 6 3/16 1/16
"Depression + ADHD" 10/14 9/14 6/14 28 ± 11 6/14 2/14
t-test p-value 0.0008
χ2-test p-value 0.825 0.261 0.151 0.151 0.464Behavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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SPECT provides image processing, tomographic recon-
struction and image display. SPECT has a lower spatial
resolution as compared to PET (8-10 mm versus 4-7 mm)
and does not allow for quantitative assessment. Neverthe-
less, brain SPECT reflects CBF and neuronal activity distri-
bution, resulting in reliable brain mapping with the use of
radiopharmaceuticals that are more easily obtainable
commercially than those applied at PET, making SPECT
the most common functional imaging technique in rou-
tine examinations. Time resolution for perfusional SPECT
is between two and three minutes, being lower than fMRI
or methodologies based on magnetic activity of the brain
(MEG). Image acquisition can be started up to some hours
after administration still representing the brain distribu-
tion of the radiopharmaceutical at the moment of injec-
tion allowing for experiments to be performed in ideal
psychological conditions in a quiet environment outside
of the camera gantry.
SPECT was analyzed with SPM and CBA, three-dimen-
sional digitized spatial standardization software which
approach statistical analysis from different points of view.
SPM implements univariate analysis creating t-statistic
based maps. CBA utilises the data from regions or VOIs
able to feed multivariate analysis enabling the investiga-
tion of more general statistical effects. SPM analysis is con-
ducted at cluster of voxel level while the CBA produces
data at the larger VOI level. SPM does not usually analyse
regions defined a priori and identifies changes only if clus-
tering in a number of voxels exceed the determined
threshold, often missing general effects. Conversely CBA
cannot analyse clusters of voxel smaller than the pre-
Voxels reflecting lower tracer uptake (blue) in the adult- ADHD depressed patients compared to the healthy controls Figure 1
Voxels reflecting lower tracer uptake (blue) in the 
adult-ADHD depressed patients compared to the 
healthy controls. Left row from top to bottom: uptake in 
the left cerebellum in as seen at a frontal view of the brain; in 
the right cerebellum at the side view of the right hemisphere; 
and in the bilateral cerebellum at the bottom view. Right 
row: uptake in the bilateral cerebellum seen at the back view 
of the brain; in the left cerebellum at the side view of the left 
hemisphere; and as barely seen (and non-significant) in the 
bilateral parieto-occipital lobe at the top view of the brain.
Voxels reflecting higher tracer uptake (red) in the adult- ADHD depressed patients compared to the depressed  patients Figure 2
Voxels reflecting higher tracer uptake (red) in the 
adult-ADHD depressed patients compared to the 
depressed patients. Left row from top to bottom: uptake 
in the frontal lobe as seen at a frontal view of the brain; in the 
right frontal lobe at the side view of the right hemisphere; 
and in the orbito-frontal lobe at the bottom view. Right row: 
the back view of the brain; in the left frontal lobe at the side 
view of the left hemisphere; and in the bilateral frontal lobe 
at the top view of the brain.Behavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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defined VOIs generally failing to detect fine regional
changes. It is thus not surprising that the two methods
might highlight different topographic changes in different
regions. Hence, the double analysis underscores their
complementarity in identifying global and local func-
tional changes.
Decreased uptake (and retention) of the tracer 99mTc-
HMPAO reflects various phenomena such as decreased
blood flow, loss of cells or cellular constituents, decreased
neuronal activity in functional circuits, and/or the meta-
bolic status of the tissue. There is no overt linear correla-
tion between the uptake of 99mTc-HMPAO and CBF as
measured at PET using O-15 labeled water in healthy sub-
jects [28,29]. Uncoupling between the 99mTc-HMPAO
uptake and the cerebral glucose metabolic rate at PET has
been reported in the left basal ganglia in depressive disor-
der [15]. Measured change in local brain activity reflects
both physiological processes and neuroenergetic mecha-
nisms. The mechanism by which 99mTc-HMPAO is intrac-
ellularly trapped and retained is also related to the
metabolic state. 99mTc-HMPAO uptake can parallel the
cellular content of reduced glutathione (GSH) [30], but
the overall retention of 99mTc-HMPAO may be more
dependent upon the redox activity than GSH content only
[31]. GSH is involved in the cellular redox balance and in
the protection against oxidative damage. In disorders of
the cellular energy production in mitochondria, an
increased cellular GSH content may occur initially in the
disease [32]. The decreased cellular GSH content that was
The differences of the 99mTc-HMPAO uptake at SPECT as analyzed by SPM2 between the adult-ADHD depressed patients and  the other groups are exemplified by left hemisphere images Figure 3
The differences of the 99mTc-HMPAO uptake at SPECT as analyzed by SPM2 between the adult-ADHD 
depressed patients and the other groups are exemplified by left hemisphere images.Behavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
Page 8 of 12
(page number not for citation purposes)
reported in a subset of patients with such conditions may
occur as a consequence of the increasing oxidative stress
that can appear with time [33].
At the comparisons between the "Depression + ADHD"
subgroup and controls, decreased tracer uptake within the
cerebellum was found at both SPM and CBA in the
patients. The cerebellum is involved in cognitive and
behavioural control and emotional processing. Lesions in
parts of the cerebellum are hypothesized to modulate
actions via a "dysmetria of thought" [9]. Decreased cere-
bellar activity has been observed at functional MRI (fMRI)
in adult-ADHD [34].
In a longitudinal MRI study of children with ADHD, there
were smaller volumes of the cerebellar vermis, and
changes over time of the total cerebellar volume in the
subgroup with worse outcome [35]. A cerebellar over cer-
ebral involvement as detected by MRI has been reported
in a quarter of patients with heterogeneous disorders
affecting the neuroenergetic metabolism in mitochondria
[36]. The cerebellar hemispheres and vermis are affected
particularly in the mitochondrial disorder associated with
deficiency of Q10, a component of the respiratory chain
which acts as an antioxidant because of its ability to trans-
fer electrons [36]. Chronic administration of methylphe-
nidate (MPD), considered to be the first-line drug in
adult-ADHD, increases the activities of mitochondrial res-
piratory chain complexes in the cerebellar vermis [37].
MPD binds to dopamine transporters implicated in the
vulnerability to ADHD which are expressed also in the cer-
ebellum, and blocks the inward transport of dopamine
[37,38]. MPD responders among ADHD patients have a
high availability for dopamine transporters in contrast to
nonresponders [39]. Since dopamine has been shown to
inhibit complex I of the mitochondrial respiratory chain
[40], the pathophysiology of ADHD may involve mito-
chondrial dysfunction which by itself has been shown to
exert effects on dopamine turnover [41,42], and/or relate
to primary alterations of dopamine transporters.
In a postmortem specimen study of major depression,
decreased expression levels of subunits of mitochondrial
complex I were found in the cerebellum. There were no
alteration in any other of the analyzed brain region. A less
consistent pattern of cerebellar reductions was observed
in bipolar disorder along with increased subunit expres-
sion in the parieto-occipital cortex [43]. In light of the
high comorbidity between mood disorders and adult-
ADHD [4-6], the cerebellar alterations in this [43] as well
as in a study of recovered patients with recurrent major
depression [44] might reflect adult-ADHD in a proportion
of the subjects. The decreased tracer uptake in the cerebel-
lum in the "Depression + ADHD" subgroup may hypo-
thetically reflect some longstanding process preferentially
affecting this brain region involving oxidative stress and
mitochondrial energy production, and/or relate to the
higher depression severity in "Depression + ADHD".
Increased tracer uptake at SPM in "Depression + ADHD"
was found at the comparisons with "Depression" in BA 32
in the bilateral anterior cingulate cortex, BAs 8, 9 and 10
in the prefrontal and middle frontal cortex, and adjacent
white matter. An increase of white matter volume has
been reported in adult-ADHD [10]. The anterior cingulate
is considered to play a critical role in complex cognitive
processing, particularly target detection, response selec-
tion, error detection, and reward-based decision-making,
functions that are thought to be impaired in ADHD [10].
Signs indicating functional hypoactivity in adult-ADHD at
PET [12] and fMRI [45] have been reported for the ante-
rior cingulate cortex, and for the premotor cortex and the
superior prefrontal cortex [11]. Failure to suppress activity
in the default-mode network in the ventral medial pre-
frontal cortex and posterior cingulate cortex, and pre-
cuneus in the midline, has been suggested as the neural
substrate of ADHD-relevant behaviour [46]. Time series
fMRI has demonstrated strong evidence of disconnection
between an anterior control region and posterior compo-
nents of this network [46].
In a metaanalysis of neuro-imaging studies of major
depression, "maximally abnormal" loci were identified
within BA 32 and 24 in the anterior cingulate, and at the
border of BAs 46 and 9 in the prefrontal cortex. Although
more studies were categorized as reporting "overactivity",
the fraction was not significant [47]. However, the
increased tracer uptake in the "Depression + ADHD" sub-
group as compared to in "Depression" in BA 32 in the
anterior cingulate cortex and BAs 8, 9 and 10 in the pre-
frontal and middle frontal cortex may not be related to the
mood differences between these groups since no differ-
ence of the tracer uptake was found between controls and
"Depression", or between controls and "Depression +
ADHD", in these regions.
Decreased tracer uptake in the frontal lobe has been
reported in most 99mTc-HMPAO SPECT studies of depres-
sion. Increased frontal lobe tracer uptake has been
reported in studies of atypical and chronic depression
[48]. Increased frontal lobe tracer uptake has also been
described in depressed patients with decreased muscle
activities of mitochondrial enzymes in comparison with
depressed patients with normal enzyme activities [49].
Compensatory strategies eliciting increased cognitive
(prefrontal, BAs 8 and 9) control were suggested to have
improved task performance in an fMRI study of ADHD
children with variable intrasubject response patterns dur-
ing task performance [50]. In the present study, the higher
99mTc-HMPAO uptake in the frontal lobe in the "Depres-Behavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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sion + ADHD" subgroup compared to in "Depression"
may reflect cellular traces of some metabolic process of a
more recent onset than the process affecting the cerebel-
lum, or higher brain activity in "Depression + ADHD" to
compensate for a "dysmetria of thought" due to a decrease
of cerebellar function.
Decreased tracer uptake was found at CBA in "Depression
+ ADHD" in the caudate nuclei ("cognitive associative
striatum") at the comparison with controls, and in the
bilateral putamen ("sensorimotor striatum") and thala-
mus at the comparison with "Depression". A caudate
involvement in ADHD has been reported [9]. Decreased
activation of the putamen and thalamus has been demon-
strated at event-related fMRI in children and adolescents
with ADHD [51,52]. An involvement of the putamen and
of networks including the thalamus has been suggested in
ADHD [9]. A putaminal involvement may reflect various
phenomena such as dysfunction of the widespread atten-
tion networks due to a disconnection between an anterior
cingulate control region with long-range connections and
posterior components [34].
The WRAADDS subscale Impulsivity and a Socialization
scale were used in the discriminant analysis due to the
specific and highly statistical group differences in these
parameters. These factors, combined with the neurophys-
iological measure of the tracer uptake in the thalami, ena-
bled a correct assignment of the cases to the "Depression"
and the "Depression + ADHD" subgroups. A high discrim-
inative value of the two scales was expected since the
Impulsivity items comprises 10% of the 60 items used at
the subgrouping, and since the Socialization items which
were formulated 50 years ago deal with aspects of inter-
personal difficulties often experienced in ADHD [see
Additional file 2]. The fact that limiting the analysis to
these scales (with a contribution of the thalami tracer dis-
tribution values) allowed for the assignment of all
patients to the correct clinical group is of great interest.
Kendell and Jablensky, in their discussion on the validity
and utility of psychiatric diagnostic criteria and rule-based
classifications, suggest that "there may be excellent rea-
sons for using quite different criteria, for example, the
presence of a single key symptom; a minimum score on a
rating scale; a cognitive, pharmacological, or neurophysi-
ological abnormality, or a combination of these" [53]. It
cannot be excluded that the contribution of thalamic
tracer uptake in discriminating between the groups
reflects more than a spurious finding since decreased tha-
lamic activation has been reported in adolescent ADHD
[52].
Evaluating the genders separately may be advantageous in
studies using 99mTc-HMPAO SPECT due to observed gen-
der differences using this method [23]. In studies compar-
ing males and females with adult-ADHD, females were
more impaired on ADHD scales, had a higher level of
emotional symptoms, a more complicated presentation,
reported fewer assets and more problems suggesting
poorer self-perception, and had increased prevalence of
affective disorder and higher somatization scores
[5,54,55].
Controlling for age onset and depression severity might
not be apt since, in females, more severe symptoms may
be inherent characteristics of depression with comorbid
adult-ADHD. Inconsistent results concerning age of onset
of major depression have been reported in studies of
depression with and without adult-ADHD [6,56,57]. No
increase of depression severity was observed in a study of
depressed patients with comorbid adult-ADHD of whom
almost half were male [56]. In females with adolescent
and adult-ADHD, major depression was associated with
an earlier age at onset, greater than twice the duration,
more severe depression-associated impairment, and a
higher rate of suicidality than major depression in females
without ADHD [57]. The higher depression severity in the
"Depression + ADHD" subgroup compared to in "Depres-
sion" may thus reflect that only females were studied.
However, the disease burden did not differ between
"Depression" and "Depression + ADHD", as exemplified
by work capacity and other indices of adult life accom-
plishments (Table 2).
Limitations
The possibility that medication could have influenced the
results cannot be fully ruled out since, although statisti-
cally unsignificant, 3/16 (19%) of the "Depression" sub-
group patients, and 6/14 (43%) of the "Depression +
ADHD" patients, had ongoing anti-depressant medica-
tions at the time of SPECT.
It is difficult to evaluate the contribution of the depressive
or the audiological symptoms or the heredity for audio-
logical symptoms, in our patients on the brain uptake of
99mTc-HMPAO, and thus the generalisability of our find-
ings to adult-ADHD. No study has to our knowledge been
performed reporting the prevalence of uni- or bilateral
audiological symptoms of cochlear origin in adult-
ADHD. There were no such symptoms in 3/16 (19%) of
the patients in the "Depression" subgroup, or in 6/14
(43%) of the "Depression + ADHD" patients, an unsignif-
icant difference. It seems unlikely that the decreased tracer
uptake in "Depression + ADHD" compared to controls is
related to audiological symptoms since the proportion is
lower in "Depression + ADHD". ADHD is more common
than expected in deaf children [58]. According to the clin-
ical experience by the first author (A.G.), ADHD in off-
spring with normal hearing of depressed patients with
uni- or bilateral audiological symptoms of various ageBehavioral and Brain Functions 2009, 5:37 http://www.behavioralandbrainfunctions.com/content/5/1/37
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onset could be more common than to be expected. Since
both audiological and mood disorders are common man-
ifestations of mitochondrial disorders [59], familial co-
occurrence is likely to be increased if there is an element
of mitochondrial dysfunction in ADHD, as has been sug-
gested [60]. A role of mitochondrial dysfunction in the
pathophysiology of bipolar disorder, a condition with
familial co-occurrence, symptom overlap and comorbid-
ity with ADHD [61,62], is supported by several findings
[43,63,64]. For comments on the issue of a shared patho-
physiology between ADHD and comorbid psychiatric and
somatic disorders, see [Additional file 1].
In the absence of well-validated and universally accepted
diagnostic criteria for adult-ADHD [6,65], our approach
using cut-off scores followed by clinical interview may
have overdiagnosed as well as underdiagnosed adult-
ADHD in the patients in whom no neuropsychological
investigation was performed.
Conclusion
In this study applying the commonly available functional
neuro-imaging method SPECT, we found decreased tracer
uptake in the bilateral cerebellum in a group of depressed
patients with adult-ADHD in comparison with healthy
controls as verified by different three-dimensional digi-
tized spatial standardization software. Increased tracer
uptake in frontal lobe regions was observed in depressed
patients with ADHD in comparison with depressed
patients without ADHD tentatively reflecting a difference
of the metabolic status in these brain regions which may
be caused by some primary biochemical phenomenon, or
reflect a compensatory mechanism, between these sub-
groups of depressed patients. Further studies are war-
ranted exploring if depression with ADHD may represent
endophenotype(s) of major depression, i.e., internal phe-
notypes that are not obvious to the unaided eye filling the
gap between available descriptors, and between the gene
and the elusive disease process, and therefore may help to
resolve questions about etiological models [66].
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